Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE(R) (STACCATO(R) Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Next Previous
Trial Profile

A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE(R) (STACCATO(R) Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Loxapine (Primary)
  • Indications Agitation
  • Focus Pharmacokinetics
  • Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

  • 15 Feb 2017 Results published in the Clinical Pharmacokinetics.
  • 21 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 06 Aug 2015 According to Alexza Pharmaceuticals media release, Teva expects to file the clinical study report later in 2015 with the U.S. Food and Drug Administration.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top